Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs.
In the past clinical trials in dementia, symptomatic or disease modifycing in nature, relied mostly on clinical/neuropsychological endpoints. In the recent past much effort has been put into incorporating imaging, notably MRI, into trials in order to provide a surrogate marker for progression and measure a disease modifying effect, and to provide more insight into the homogeneity, or absence of, the included sample. In the following review an update will be given on the current thinking on how and when MRI should be used in the design of a clinical trial in Alzheimer's disease and mild cognitive impairment, with particular emphasis on trials focusing on disease modification.
Scheltens
P
P
Dept. Neurology and Alzheimer Center. VU University Medical Center. p.scheltens@vumc.nl
Barkhof
F
F
D000544:Alzheimer Disease / Q000145:classification / Q000175:diagnosis* / Q000473:pathology; D002986:Clinical Trials as Topic; D003704:Dementia / Q000145:classification / Q000175:diagnosis* / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D017063:Outcome Assessment, Health Care / Q000379:methods* / Q000592:standards*